$RTTR 01:39 PM EDT, 05/02/2017 (MT Newswires) --
Post# of 23116
(Total Views: 207)
Posted On: 05/02/2017 1:44:39 PM
$RTTR
01:39 PM EDT, 05/02/2017 (MT Newswires) -- Shares of Ritter Pharmaceuticals (RTTR), a developer of products that modulate the human gut microbiome, jumped more than 25% after touching their lowest level ever, as the company said Tuesday it has been issued three new patents directed to its development compound RP-G28. It also provided an update on a phase 3 program.
The company has received two new U.S. patents and one new Australian patent, it said in a statement.
The U.S. patents -- 9,579,340 and 9,592,248 -- are directed to compositions containing RP-G28 and methods of using RP-G28, further strengthening the intellectual property positions of RP-G28.
The Australian patent -- 20102184 -- provides additional international protection for compositions containing the compound.
In addition to the new intellectual property, the company has been working on preparing for phase 3, having had preliminary discussions with its regulatory experts and the U.S. Food and Drug Administration (FDA).
"We will be holding an end of phase 2 meeting with the FDA to present and discuss our phase 3 plan, for which we hope to receive guidance and agreement on what is expected before filing a new drug application (NDA) for commercializing RP-G28," said Andrew Ritter, president of Ritter.
"We believe that the completion of one well-powered phase 3 study with robust clinical results may be sufficient to successfully file this NDA," he noted.
RP-G28 is being developed as a treatment for lactose intolerance.
The new 52-week price range for the shares is $0.68 - $3.75.
Price: 0.92, Change: +0.19, Percent Change: +25.67
http://www.mtnewswires.com Copyright © 2017 MTNewswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
01:39 PM EDT, 05/02/2017 (MT Newswires) -- Shares of Ritter Pharmaceuticals (RTTR), a developer of products that modulate the human gut microbiome, jumped more than 25% after touching their lowest level ever, as the company said Tuesday it has been issued three new patents directed to its development compound RP-G28. It also provided an update on a phase 3 program.
The company has received two new U.S. patents and one new Australian patent, it said in a statement.
The U.S. patents -- 9,579,340 and 9,592,248 -- are directed to compositions containing RP-G28 and methods of using RP-G28, further strengthening the intellectual property positions of RP-G28.
The Australian patent -- 20102184 -- provides additional international protection for compositions containing the compound.
In addition to the new intellectual property, the company has been working on preparing for phase 3, having had preliminary discussions with its regulatory experts and the U.S. Food and Drug Administration (FDA).
"We will be holding an end of phase 2 meeting with the FDA to present and discuss our phase 3 plan, for which we hope to receive guidance and agreement on what is expected before filing a new drug application (NDA) for commercializing RP-G28," said Andrew Ritter, president of Ritter.
"We believe that the completion of one well-powered phase 3 study with robust clinical results may be sufficient to successfully file this NDA," he noted.
RP-G28 is being developed as a treatment for lactose intolerance.
The new 52-week price range for the shares is $0.68 - $3.75.
Price: 0.92, Change: +0.19, Percent Change: +25.67
http://www.mtnewswires.com Copyright © 2017 MTNewswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
(0)
(0)